Onkure Therapeutics, Stock Performance
| OKUR Stock | 8.38 0.33 4.10% |
The company holds a Beta of 0.23, which implies not very significant fluctuations relative to the market. As returns on the market increase, OnKure Therapeutics,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding OnKure Therapeutics, is expected to be smaller as well. At this point, OnKure Therapeutics, has a negative expected return of -0.67%. Please make sure to check OnKure Therapeutics,'s jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if OnKure Therapeutics, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days OnKure Therapeutics, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with fragile performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 4.1 | Five Day Return (13.52) | Year To Date Return (49.52) | Ten Year Return (94.41) | All Time Return (94.41) |
1 | Acquisition by Saccomano Nicholas A of 4556 shares of OnKure Therapeutics, subject to Rule 16b-3 | 10/08/2024 |
2 | Acquisition by Leonard Braden Michael of 3457 shares of OKUR New subject to Rule 16b-3 | 10/09/2024 |
3 | This Builders FirstSource Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Thursday | 10/10/2024 |
4 | Acquisition by Manke Isaac of 15300 shares of OnKure Therapeutics, at 18.2 subject to Rule 16b-3 | 10/18/2024 |
5 | OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium | 11/01/2024 |
6 | Acquisition by Jansen Valerie Malyvanh of 15300 shares of OnKure Therapeutics, at 18.2 subject to Rule 16b-3 | 11/22/2024 |
7 | OnKure Announces New Date for Upcoming Investor Call | 11/25/2024 |
8 | OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic Data from its First-In-Human PIKture-01 Trial of OKI-219 | 12/10/2024 |
OnKure |
OnKure Therapeutics, Relative Risk vs. Return Landscape
If you would invest 1,380 in OnKure Therapeutics, on September 23, 2024 and sell it today you would lose (542.00) from holding OnKure Therapeutics, or give up 39.28% of portfolio value over 90 days. OnKure Therapeutics, is currently does not generate positive expected returns and assumes 4.2611% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than OnKure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
OnKure Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OnKure Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as OnKure Therapeutics,, and traders can use it to determine the average amount a OnKure Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.158
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OKUR |
Estimated Market Risk
| 4.26 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.67 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average OnKure Therapeutics, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OnKure Therapeutics, by adding OnKure Therapeutics, to a well-diversified portfolio.
OnKure Therapeutics, Fundamentals Growth
OnKure Stock prices reflect investors' perceptions of the future prospects and financial health of OnKure Therapeutics,, and OnKure Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OnKure Stock performance.
| Net Income | (35.31 M) | ||||
| Total Debt | 137.58 M | ||||
| Total Asset | 35.73 M | ||||
| Retained Earnings | (102.05 M) | ||||
About OnKure Therapeutics, Performance
Assessing OnKure Therapeutics,'s fundamental ratios provides investors with valuable insights into OnKure Therapeutics,'s financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the OnKure Therapeutics, is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
OnKure Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about OnKure Therapeutics, performance evaluation
Checking the ongoing alerts about OnKure Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for OnKure Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OnKure Therapeutics, generated a negative expected return over the last 90 days | |
| OnKure Therapeutics, has high historical volatility and very poor performance | |
| OnKure Therapeutics, has a very high chance of going through financial distress in the upcoming years | |
| OnKure Therapeutics, was previously known as Reneo Pharmaceuticals and was traded on NASDAQ Exchange under the symbol RPHM. | |
| Net Loss for the year was (35.31 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| OnKure Therapeutics, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic Data from its First-In-Human PIKture-01 Trial of OKI-219 |
- Analyzing OnKure Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OnKure Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining OnKure Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OnKure Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of OnKure Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OnKure Therapeutics,'s stock. These opinions can provide insight into OnKure Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for OnKure Stock Analysis
When running OnKure Therapeutics,'s price analysis, check to measure OnKure Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OnKure Therapeutics, is operating at the current time. Most of OnKure Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of OnKure Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OnKure Therapeutics,'s price. Additionally, you may evaluate how the addition of OnKure Therapeutics, to your portfolios can decrease your overall portfolio volatility.